Goldman Sachs initiated coverage of Glaukos (GKOS) with a Buy rating and $103 price target The company’s transformation transitions it from a device to hybrid device/ophthalmic pharmaceutical company, the analyst tells investors in a research note. The firm believes this will create a “durable” revenue growth profile that remains underappreciated in consensus expectations.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GKOS:
- 3 Best Stocks to Buy Now, 9/29/2025, According to Top Analysts
- Glaukos breaks ground on new R&D, manufacturing facility in Alabama
- Glaukos price target lowered to $120 from $126 at Truist
- Stifel sees opportunity in Glaukos selloff, adds to Select List
- Glaukos Receives Buy Rating from Analyst Ryan Zimmerman Due to Strong Growth and Promising Product Potential